Gravita India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 22, 2025, 3:54 am

Competitors of Gravita India Ltd

All Competitor Stocks of Gravita India Ltd

Quarterly Result

Last Updated: August 1, 2025, 8:40 pm

Below is a detailed analysis of the quarterly data for Gravita India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,037.00 Cr. (Mar 2025) to 1,040.00 Cr., marking an increase of 3.00 Cr..
• For Expenses, as of Jun 2025, the value is 939.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 945.00 Cr. (Mar 2025) to 939.00 Cr., marking a decrease of 6.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 92.00 Cr. (Mar 2025) to 101.00 Cr., marking an increase of 9.00 Cr..
• For OPM %, as of Jun 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 10.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 6.00 Cr..
• For Interest, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
• For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 115.00 Cr. (Mar 2025) to 116.00 Cr., marking an increase of 1.00 Cr..
• For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Mar 2025) to 20.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 95.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 2.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 12.64. The value appears to be declining and may need further review. It has decreased from 12.89 (Mar 2025) to 12.64, marking a decrease of 0.25.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:16 am

Growth

Last Updated: September 5, 2025, 5:20 am

Balance Sheet

Last Updated: May 13, 2025, 3:28 pm

Below is a detailed analysis of the balance sheet data for Gravita India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,055.00 Cr.. The value appears strong and on an upward trend. It has increased from 824.00 Cr. (Mar 2024) to 2,055.00 Cr., marking an increase of 1,231.00 Cr..
• For Borrowings, as of Mar 2025, the value is 286.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 548.00 Cr. (Mar 2024) to 286.00 Cr., marking a decrease of 262.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 159.00 Cr.. The value appears to be improving (decreasing). It has decreased from 217.00 Cr. (Mar 2024) to 159.00 Cr., marking a decrease of 58.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,515.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,602.00 Cr. (Mar 2024) to 2,515.00 Cr., marking an increase of 913.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 436.00 Cr.. The value appears strong and on an upward trend. It has increased from 348.00 Cr. (Mar 2024) to 436.00 Cr., marking an increase of 88.00 Cr..
• For CWIP, as of Mar 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 4.00 Cr..
• For Investments, as of Mar 2025, the value is 528.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2024) to 528.00 Cr., marking an increase of 512.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,512.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,194.00 Cr. (Mar 2024) to 1,512.00 Cr., marking an increase of 318.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,602.00 Cr. (Mar 2024) to 2,515.00 Cr., marking an increase of 913.00 Cr..

Notably, the Reserves (2,055.00 Cr.) exceed the Borrowings (286.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gravita India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 45.11. This value is within the healthy range. It has increased from 34.88 (Mar 24) to 45.11, marking an increase of 10.23.
• For Diluted EPS (Rs.), as of Mar 25, the value is 45.11. This value is within the healthy range. It has increased from 34.88 (Mar 24) to 45.11, marking an increase of 10.23.
• For Cash EPS (Rs.), as of Mar 25, the value is 46.34. This value is within the healthy range. It has increased from 40.59 (Mar 24) to 46.34, marking an increase of 5.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 280.48. It has increased from 123.18 (Mar 24) to 280.48, marking an increase of 157.30.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 280.48. It has increased from 123.18 (Mar 24) to 280.48, marking an increase of 157.30.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 524.22. It has increased from 457.75 (Mar 24) to 524.22, marking an increase of 66.47.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 59.07. This value is within the healthy range. It has increased from 52.33 (Mar 24) to 59.07, marking an increase of 6.74.
• For PBIT / Share (Rs.), as of Mar 25, the value is 55.13. This value is within the healthy range. It has increased from 46.83 (Mar 24) to 55.13, marking an increase of 8.30.
• For PBT / Share (Rs.), as of Mar 25, the value is 49.25. This value is within the healthy range. It has increased from 39.70 (Mar 24) to 49.25, marking an increase of 9.55.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has increased from 35.09 (Mar 24) to 42.40, marking an increase of 7.31.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.33. This value is within the healthy range. It has increased from 34.64 (Mar 24) to 42.33, marking an increase of 7.69.
• For PBDIT Margin (%), as of Mar 25, the value is 11.26. This value is within the healthy range. It has decreased from 11.43 (Mar 24) to 11.26, marking a decrease of 0.17.
• For PBIT Margin (%), as of Mar 25, the value is 10.51. This value is within the healthy range. It has increased from 10.23 (Mar 24) to 10.51, marking an increase of 0.28.
• For PBT Margin (%), as of Mar 25, the value is 9.39. This value is below the healthy minimum of 10. It has increased from 8.67 (Mar 24) to 9.39, marking an increase of 0.72.
• For Net Profit Margin (%), as of Mar 25, the value is 8.08. This value is within the healthy range. It has increased from 7.66 (Mar 24) to 8.08, marking an increase of 0.42.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.07. This value is within the healthy range. It has increased from 7.56 (Mar 24) to 8.07, marking an increase of 0.51.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.09. This value is within the healthy range. It has decreased from 28.56 (Mar 24) to 15.09, marking a decrease of 13.47.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.82. This value is within the healthy range. It has decreased from 29.08 (Mar 24) to 17.82, marking a decrease of 11.26.
• For Return On Assets (%), as of Mar 25, the value is 12.42. This value is within the healthy range. It has decreased from 14.92 (Mar 24) to 12.42, marking a decrease of 2.50.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.09, marking a decrease of 0.20.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.13. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.13, marking a decrease of 0.52.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.88. It has decreased from 2.25 (Mar 24) to 1.88, marking a decrease of 0.37.
• For Current Ratio (X), as of Mar 25, the value is 8.43. This value exceeds the healthy maximum of 3. It has increased from 2.40 (Mar 24) to 8.43, marking an increase of 6.03.
• For Quick Ratio (X), as of Mar 25, the value is 5.78. This value exceeds the healthy maximum of 2. It has increased from 1.02 (Mar 24) to 5.78, marking an increase of 4.76.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.99. This value is within the healthy range. It has increased from 4.03 (Mar 24) to 5.99, marking an increase of 1.96.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.32. This value is below the healthy minimum of 20. It has decreased from 12.33 (Mar 24) to 11.32, marking a decrease of 1.01.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.36. This value is below the healthy minimum of 20. It has decreased from 10.64 (Mar 24) to 10.36, marking a decrease of 0.28.
• For Earning Retention Ratio (%), as of Mar 25, the value is 88.68. This value exceeds the healthy maximum of 70. It has increased from 87.67 (Mar 24) to 88.68, marking an increase of 1.01.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.64. This value exceeds the healthy maximum of 70. It has increased from 89.36 (Mar 24) to 89.64, marking an increase of 0.28.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 10.05. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 10.05, marking an increase of 2.71.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.21. This value is within the healthy range. It has increased from 5.92 (Mar 24) to 8.21, marking an increase of 2.29.
• For Enterprise Value (Cr.), as of Mar 25, the value is 13,364.10. It has increased from 7,350.02 (Mar 24) to 13,364.10, marking an increase of 6,014.08.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.45. This value exceeds the healthy maximum of 3. It has increased from 2.33 (Mar 24) to 3.45, marking an increase of 1.12.
• For EV / EBITDA (X), as of Mar 25, the value is 30.66. This value exceeds the healthy maximum of 15. It has increased from 20.34 (Mar 24) to 30.66, marking an increase of 10.32.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.48. This value exceeds the healthy maximum of 3. It has increased from 2.18 (Mar 24) to 3.48, marking an increase of 1.30.
• For Retention Ratios (%), as of Mar 25, the value is 88.67. This value exceeds the healthy maximum of 70. It has increased from 87.66 (Mar 24) to 88.67, marking an increase of 1.01.
• For Price / BV (X), as of Mar 25, the value is 6.51. This value exceeds the healthy maximum of 3. It has decreased from 8.23 (Mar 24) to 6.51, marking a decrease of 1.72.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.48. This value exceeds the healthy maximum of 3. It has increased from 2.18 (Mar 24) to 3.48, marking an increase of 1.30.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness